Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND2 | P30279 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681867 | 0.78 | CDK4 (0.40) | SMN1; SMN2MAPTLMNANPC1RAB9A | |
| SCHEMBL10597853 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL336560 | 0.72 | — | — | |
| SCHEMBL9083546 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPTLMNANPC1RAB9A | |
| SCHEMBL12288410 | 0.72 | HDAC6 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15730527 | 0.71 | HDAC6 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL12883333 | 0.71 | ALDH1A1 (0.46) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17036646 | 0.71 | KDM4E (0.57) | SMN1; SMN2MAPTLMNACDK4CCND1 | |
| SCHEMBL5966347 | 0.70 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTLMNANPC1RAB9A | |
| SCHEMBL21540587 | 0.70 | VNN1 (0.49) | KDM4EHDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3448851-B1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-109476635-B | Disubstituted pyrazoles for treatment of diseases | FGH生物科技公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| WO-2017190086-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-2809321-B1 | PHENYL-C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION FOR USE IN COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2606045-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8658661-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2606045-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012024150-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | SMN1; SMN2 4574/4885MAPT 3234/4885LMNA 1555/4885 |
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | SMN1; SMN2 4574/4885MAPT 3234/4885LMNA 1555/4885 |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | SMN1; SMN2 4270/4885MAPT 4668/4885LMNA 1745/4885 |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | SMN1; SMN2 4574/4885MAPT 3234/4885LMNA 1555/4885 |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | SMN1; SMN2 4337/4885MAPT 4716/4885LMNA 2335/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | SMN1; SMN2 3750/4885MAPT 3602/4885LMNA 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.